Login
Subscribe
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
drug development, neurodegeneration
Replacing Microglia Treats Neurodegenerative Disease in Mice
Shawna Williams | Mar 17, 2022 | 2 min read
Researchers find a way to wipe out the brain’s immune cell corps and send in new and improved versions.
Repurposed Drug Reverses Signs of Alzheimer’s in Mice, Human Cells
Jef Akst | Oct 12, 2021 | 2 min read
Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.
Biogen Defends Newly Approved Alzheimer’s Drug
Jef Akst | Jul 27, 2021 | 3 min read
The US Food and Drug Administration has called for a federal investigation of its own regulatory review process after widespread criticism of its decision on Aduhelm.
Inhaled Antibody Fragments Protect Infected Animals Against COVID-19
Roni Dengler, PhD | Jun 14, 2021 | 2 min read
Tiny but powerful nanobodies may be the innovation that snuffs out the pandemic.
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
Kerry Grens | Jun 7, 2021 | 2 min read
A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.
Eli Lilly Claims New Drug Can Slow Alzheimer’s-Related Decline
Lisa Winter | Mar 16, 2021 | 2 min read
Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.
New Drug Combo for ALS Slows Decline in Small Clinical Study
Jef Akst | Sep 3, 2020 | 3 min read
After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.
Flu and Pneumonia Vaccines Linked to Reduced Risk of Alzheimer’s
Amanda Heidt | Jul 27, 2020 | 3 min read
The authors propose that the shots might keep the immune system primed to battle diseases that would otherwise contribute to cognitive decline.
Interactive: Biomarkers in Blood Provide a Window into the Brain
Shawna Williams | Dec 1, 2019 | 1 min read
A look at some of the circulating molecules that may indicate various Alzheimer’s pathologies and serve as the bases of noninvasive tests for the disease.
The Hunt for a Blood Test for Alzheimer’s Disease
Shawna Williams | Dec 1, 2019 | 10 min read
Researchers hope circulating biomarkers will enable earlier detection and better monitoring of the neurodegenerative disorder—and perhaps help usher in new treatments.
China Approves Alzheimer’s Treatment that Targets the Microbiome
Kerry Grens | Nov 5, 2019 | 2 min read
Oligomannate, derived from a compound in seaweed, suppresses neural inflammation caused by gut bacteria in mice.
Microglia Remember Bouts of Bodily Inflammation in Mice
Ashley Yeager | Apr 11, 2018 | 2 min read
A new study reports that immune memory may contribute to neurodegenerative diseases.
Second-Ever ALS Drug Approved
Jef Akst | May 8, 2017 | 2 min read
Amyotrophic lateral sclerosis patients in the U.S. now have an option besides riluzole, which was approved by the FDA more than two decades ago and only extends life by two or three months.
New Support for Experimental Alzheimer’s Drug
Jef Akst | Nov 2, 2016 | 2 min read
Merck’s verubecestat, which is currently being tested in two Phase 3 studies, is safe, according to newly published Phase 1 data.
Alzheimer’s in the Blood
Jef Akst | Jul 23, 2014 | 5 min read
Researchers are on a mission to identify blood-borne biomarkers for dementia. Will this year’s high-profile successes pave the way?